Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE)

Mounting evidence supports complete metastatic ablation for oligometastatic cancer but the relevance of this approach to oligometastatic prostate cancer (OMPC) remain an area of active study. Importantly, biomarkers to determine patients who benefit most from complete ablation are unknown. We hypothesize that stereotactic ablative radiation (SABR) will improve oncologic outcomes in men with OMPC.

Source: International Journal of Radiation Oncology * Biology * Physics - September 18, 2019 Category: Radiology Authors: R. Phillips, S.J. Lim, W.Y. Shi, E.S. Antonarakis, S. Rowe, M. Gorin, C. Deville, S.C. Greco, S. Denmeade, C. Paller, T.L. DeWeese, D. Song, H. Wang, M. Carducci, K. Pienta, M.G. Pomper, A.P. Dicker, M. Eisenberger, M. Diehn, P.T. Tran Source Type: research